INTRODUCTION
colorectal cancer, tumor, CRC, toxicity, cancer, various malignant tumors
COLORECTAL CANCER, TUMOR, ONCOGENESIS, CANCER, TUMOR ANGIOGENESIS, ONCOLOGY
Globally, colorectal cancer (CRC) ranks third in incidence and second in tumor‐related mortality among various malignant tumors in the world.Fruquintinib is a potent and highly selective small‐molecule inhibitor of vascular endothelial growth factor receptor (VEGFR)‐1, ‐2, and ‐3 that inhibit tumor angiogenesis.In clinical practice, physicians often use various dose reduction or interval regimens to address the challenges faced by elderly patients who may exhibit poor tolerance to treatments, despite the lack of supportive clinical data. It is noteworthy that these strategies draw inspiration from the utilization of regorafenib. Regorafenib, an oral multitargeted kinase inhibitor, blocks several protein kinases involved in angiogenesis, oncogenesis, and tumor microenvironment.The International Society of Geriatric Oncology has initially proposed that comprehensive geriatric assessment (GA) may help predict cancer treatment‐related toxicity and survival, as well as guide the choice and intensity of treatment.Here, we report the efficacy and safety of fruquintinib dose‐escalation strategy for elderly refractory mCRC patients. Meanwhile, this study explored whether GA can predict the efficacy of fruquintinib treatment in elderly patients with mCRC.